Solid Biosciences (SLDB) announced that the first participant has been dosed in IMPACT DUCHENNE, the company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003 for the treatment of Duchenne muscular dystrophy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences receives orphan drug designation for SGT-003 from EC
- Solid Biosciences Adjusts Board Classes in Governance Move
- Solid Biosciences price target raised to $12 from $11 at JPMorgan
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
- Solid Biosciences: Strong SGT-003 Clinical Profile, Emerging Pipeline, and Robust Cash Runway Underpin Buy Rating